Subcutaneous delivery method

By employing smaller needles and controlled infusion rates with energy storage pumps, the method addresses tissue damage and pain in subcutaneous drug delivery, achieving effective and safe drug absorption without complications.

WO2026232181A1PCT designated stage Publication Date: 2026-11-12PALMAYA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/AU2025/050455
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-05
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current subcutaneous drug delivery methods cause tissue damage and pain due to high infusion rates and concentrations, leading to complications such as abscesses, infections, and tissue necrosis.

Method used

The method involves using smaller needles with a 5-18 thousands of an inch diameter and a length of 2 to 10 mm, combined with infusion rates of 1 to 4 ml/hour, and diluting therapeutic agents to concentrations between 0.5g/100 ml to 4g/10 ml, administered over a continuous infusion rate of about 1 to 8 ml/hour, utilizing energy storage pumps like Springfusor™ or elastomer pumps for controlled delivery.

Benefits of technology

This approach significantly reduces tissue damage and pain by ensuring the infusion rate matches or exceeds tissue absorption, maintaining therapeutic efficacy while minimizing mechanical and chemical damage, achieving similar blood levels to continuous intravenous delivery.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention is directed towards improving the subcutaneous delivery of a therapeutically effective amount of a drug to a patient in need thereof to avoid, reduce or eliminate tissue damage and / or pain associated with the delivery of the drug at or around the site of administration.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] SUBCUTANEOUS DELIVERY METHOD

[0002] TECHNICAL FIELD

[0003] The present invention relates to an improved method of subcutaneously delivering a therapeutically effective amount of an active agent, such as an antibiotic, to a patient in need thereof. In particular, the method involves the avoidance, reduction, or elimination of tissue damage and / or pain at the site of delivery of the therapeutically effective active agent associated with known subcutaneous injection techniques.

[0004] BACKGROUND ART

[0005] The following discussion of the background art is intended to facilitate an understanding of the present invention only. The discussion is not an acknowledgement or admission that any of the material referred to is or was part of the common general knowledge as at the priority date of the application.

[0006] The route of administration of a drug is usually classified by the location where the drug is administered. For example, a drug may be administered orally or by intravenous injection. The route of administration may also be classified based on the site of action. Thus, a drug may be administered topically (local), enterally (system-wide effect, delivered through the gastrointestinal tract), or parenterally (systemic action, delivered by routes other than the gastrointestinal tract). Delivery of a drug via injection, includes subcutaneous, intravenous, intramuscular, and intrathecal administration.

[0007] Intravenous administration is generally recommended to treat severe life-threatening infections and deep-seated infections due to concerns in achieving a therapeutically effective concentrations of the antibiotic at the site of infection. Patients who are unable to absorb or take oral drugs require this type of administration. This route is also recommended in immunocompromised patients due to their reduced ability to fight infection. A drug may also be manufactured or prepared as an injection to prolong drug absorption from the injection site for hours, days, or longer. Such drugs do not need to be administered as often as drug with a more rapid rate of absorption.

[0008] Drugs, such as antibiotics may be delivered via an injection as a bolus dose at volumes of 10 ml, 20 ml or more, typically over a period of about 5 to 30 minutes. When delivering an antibiotic at volumes as high as 20 ml over 5 minutes or 20 ml over 30 minutes, the subcutaneous infusion rate is usually between about 240 to 40 ml per hour.

[0009] For drugs administered via the subcutaneous route, a needle is inserted into the fatty tissue just beneath the skin. After the drug is injected, the drug moves via the small blood vessels into the bloodstream. Alternatively, the drug can reach the bloodstream through the lymphatic vessels.Protein drugs of a large size, such as insulin, usually reach the bloodstream through the lymphatic vessels since these drugs move slowly from the tissues into capillaries. The subcutaneous route is used for many protein drugs because such drugs would be destroyed in the digestive tract if they were orally administered.

[0010] Where the therapeutic agent is administered via injection, including via subcutaneous injection, there is a risk of damaging the tissue at the injection site.

[0011] Certain drugs (such as progestins) may be administered by inserting the encapsulated drugs under the skin as an implant. Although this route of administration is not as commonly used as other forms of drug delivery, the main advantage is to provide a long-term therapeutic effect of the drug.

[0012] Many drugs are administered orally as liquids, capsules, tablets, or chewable tablets. Because the oral route is the most convenient and usually the safest and least expensive, it is the one that is most often used. However, oral administration has its limitations, generally as a result of the passage of the drug through the digestive tract. For drugs administered orally, absorption may begin in the mouth and stomach. However, most drugs are usually absorbed from the small intestine. The drug passes through the intestinal wall and travels to the liver before being transported via the bloodstream to the site of action. The drug may undergo a chemical change within the gastrointestinal tract or liver, decreasing the amount of drug that reaches the bloodstream. Therefore, drugs not suitable for oral administration are often given in smaller doses when injected intravenously to produce the same effect.

[0013] Despite the variety of routes to administer a therapeutically effective amount of a drug, not all the route of administration currently used to deliver the drugs are without their disadvantages. The present invention seeks to overcome, or at least ameliorate, one or more of the deficiencies of the prior art mentioned above, or to provide the consumer with a useful or commercial choice. SUMMARY OF INVENTION

[0014] The present invention is directed towards improving the subcutaneous delivery of a therapeutically effective amount of a drug to a patient in need thereof to avoid, reduce or eliminate tissue damage and / or pain associated with the delivery of the drug at or around the site of administration.

[0015] The inventors have found that when delivering a pharmaceutical composition by subcutaneous injection to a subject in need thereof, reducing the infusion rate (ml / hour) avoids, reduces or eliminates damage to the tissue at or around the site of injection. Preferably, the infusion rate of the fluid associated with the pharmaceutical composition is substantially the same as, similar to or less than the rate that the fluid is absorbed by the tissue at or around the injection site.In one aspect of the present invention, there is provided a method to avoid, reduce or eliminate tissue damage associated with subcutaneous injection of a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutic agent in a fluid, the method comprising the use of one or more needles, wherein the size of the needle is about 2 to about 10 mm in length and has a 5-18 thousands of an inch diameter inserted vertices to skin, wherein the infusion rate of the pharmaceutical composition is about 1 ml / hour to 4 ml / hour, and wherein the infusion rate of the fluid is substantially the same as, similar to or less than the rate that the fluid is absorbed by the tissue at or around the injection site.

[0016] In a further aspect of the present invention, there is provided a method to avoid, reduce or eliminate tissue damage associated with subcutaneous injection of a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutic agent in a fluid, the method comprising diluting the amount of the therapeutic agent to a concentration that is between 0.5g / 100 ml to 4g / 10 ml administered over a continuous infusion rate of about 1 ml / hour to about 8 ml / hour.

[0017] In another aspect of the present invention, there is provided a kit which achieves the method of the invention.

[0018] In one embodiment, there is provided a kit for the subcutaneous continuous delivery of a therapeutic agent, comprising:

[0019] (i) an energy storage pump device (such as spring driven pump or elastomer pump);

[0020] (ii) a length of calibrated tubing;

[0021] (ii) at least one ampoule comprising the therapeutic agent;

[0022] (iii) a saline solution in an ampoule(s) or bag(s);

[0023] and optionally one or more needles suitable for subcutaneous injection, and instructions for use.

[0024] DESCRIPTION OF EMBODIMENTS

[0025] General

[0026] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention includes all such variation and modifications. The invention also includes all of the steps, features, formulations and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.

[0027] Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read andconsidered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness.

[0028] Any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.

[0029] The present invention is not to be limited in scope by any of the specific embodiments described herein. These embodiments are intended for the purpose of exemplification only. Functionally equivalent products, formulations and methods are clearly within the scope of the invention as described herein.

[0030] The invention described herein may include one or more range of values (e.g. size, displacement and field strength). A range of values will be understood to include all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range.

[0031] Other definitions for selected terms used herein may be found within the detailed description of the invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which the invention belongs.

[0032] As used herein “patient” or "subject” refers to any mammal, including human beings and nonhuman animals. Generally, the present invention is concerned with the treatment of humans, although the compositions and methods of the present invention may be useful to treat other mammals. Accordingly, the subject in whom the present invention may find specific utility includes, by way of illustration: humans, companion animals, other mammals, and birds.

[0033] The term “pharmaceutical composition” means a composition used in the treatment of a disease, disorder or condition and comprises at least a therapeutically effective amount of an active agent in a fluid, wherein the fluid is suitable for injection or formulated to be injected into a subject for subcutaneous injection.

[0034] The terms “drug”, “therapeutically effective active agent”, “active agent”, “compound”, "medicine”, or “medication” may be used interchangeably and have the same meaning, unless indicated otherwise. The terms essentially means that after the administration of the drug the treatment results in a useful or favorable result. The term may mean one active agent or may encompass two or more active agents.

[0035] The active agent may be an antibiotic or other viscous medication. Antibiotics that may be used in the subcutaneous delivery method of the present invention include, but are not limited to,cephalosporins, ceftriaxone, cefazolin, ertapenem, teicoplanin, amoxicillin and other penicillins and also aminoglycosides.

[0036] Diseases that may be treated with the subcutaneous delivery method include any disease or condition that may be treated with antibiotics, or in the treatment of a cancer, for example, in the delivery of chemotherapeutic drugs. Our change over the prior art is the continuous subcutaneous drug delivery over many days rather than intermittent injections subcutaneously every 6, 8, or 12 hourly. Any disease, condition or disorder that can be treated by subcutaneous delivery of an active agent known to the skilled addressee may be treated by the use of the improved method of the present invention.

[0037] By way of example, when the therapeutic agent is an antibiotic, the antibiotic may be used to treat pneumonia, urinary tract infections, intra-abdominal infections, gram negative bacterium, acute exacerbations of chronic lung disease, skin and soft tissue infections, or bone and joint infections.

[0038] When the disease to be treated is a cancer, the type of cancer will dictate the chemotherapeutic or cancer agent that is to be subcutaneously administered via the method of the present invention. For example, the agent may be selected from any of the interleukins recommended for the treatment of cancer in a patient in need thereof.

[0039] The term “infusion rate” or “delivery rate” of a pharmaceutical composition comprising a therapeutic agent in a fluid may be used interchangeably, unless indicated otherwise. The term means the rate, such as ml / hour or mi / minute, in which a pharmaceutical composition is subcutaneously injected into the subject in need thereof.

[0040] Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

[0041] Detailed Description of the Invention

[0042] The present invention involves designing an improved delivery system for viscous medications, including antibiotics, designed to eliminate the use of central lines that convey infections from the heart to tissues around the body. This has led to 30,000 deaths a year in the US from organisms often resistant to antibiotics. The invention involves continuous infusion of drugs, such as antibiotics via subcutaneous delivery.

[0043] The present inventor surprising found that the continuous subcutaneous administration of, for example antibiotics, maintains ideal Mean Inhibitory Concentrations (MIC). As such, the continuous subcutaneous delivery achieved similar blood levels to continuous intravenous delivery blood levels.By creating the first kits with spring driven and elastomer pumps, the present inventor can, by calculating the concentration and viscosity of the fluid to be delivered, make it easy for nonmedical staff and the relatives of patients to follow simple instructions, push a needle below the fat, fill and attach the pump and have blood levels of antibiotics better than or equal to that achieved in most intensive care units around the world. All of this is achieved by being first in the world to discover the value of simple kits that deliver the right drug in the right concentration at the right rate with the right viscosity, pH and temperature and validating that tissues are not injured.

[0044] The inventor has found over the course of three years that in studies with patient data sets associated with the above using cefazolin are a significant inventive breakthrough in delivering higher MIC levels to help more people escape death from infections as well as keeping more people out of hospital by moving away from intravenous technology for antibiotic infusions and by helping to eliminate the practice of leaving central and PICC (peripheral central catheters) in place for weeks or months without understanding how many deaths these cause.

[0045] The subcutaneous administration of a drug is achieved by inserting a needle into the fatty tissue just beneath the skin. Recommended sites for subcutaneous injection include the lateral aspects of the upper arm and thigh, the umbilical region of the abdomen, the back and lower loins.

[0046] Unlike muscle, subcutaneous tissue does not have a rich blood supply, and absorption of drugs delivered via this route is slower than via the intramuscular route. With a continuous infusion this does not matter as a steady state is achieved. It is often suggested that the subcutaneous route is relatively pain free. However, the inventor is aware of sufficient evidence supporting this assertion is untrue in many instances if the rate of injection is too high or the concentration of the therapeutic agent is too high.

[0047] For example, the inventor has noted complications associated with subcutaneous injections including the formation of abscesses and, in patients who require frequent injections, there is a risk of an accumulation of fat under the skin. In addition, increased infection rates have been observed at the site of injection. In extreme cases, infections may lead to septicaemia. Tissue necrosis and inflammation has also been observed at or around the delivery site. Tissue damage is believed to occur as a result of the injection fluid. These events have been seen with intermittent injections but not with continuous infusions.

[0048] As mentioned above, tissue damage at the site of administration has been observed, and may be attributed to either mechanical damage, chemical damage, or a combination of both caused by the present subcutaneous delivery methods.

[0049] Mechanical damage can be considered as the damage resulting from, at least in part, the rate in which a subcutaneous injection is delivered. The current practice is to deliver a large volume ofthe drug, such as an antibiotic, over a short period of time. For example, an antibiotic may be injected at a rate of about 100 ml / hour. Similarly, a dose of 60 ml may be delivered subcutaneously over a relatively short period of time, causing damage and often pain at the site of delivery. In generally, current delivery rates range from about 5 minutes to about 40 minutes, depending on the volume of the fluid administered. The present invention aims to reduce the mechanical damage caused to the tissue using these current subcutaneous practices.

[0050] Chemical damage can be considered as damage resulting from, at least in part, the concentration of the therapeutic agent and / or the excipient(s) or adjuvants used in the delivery fluid. That is, the dilution of the drug is important and is a balance between achieving a therapeutically effective amount of the drug. If the drug is not adequately diluted, the drug will occur at toxic levels at the site of injection. The present invention aims to reduce the chemical damage caused to the tissue using these current subcutaneous practices.

[0051] Needle size is measured in gauges (diameter of the needle) - a 25G is commonly used for subcutaneous injections. Softer cannulae are ideal for prolonged infusions. Needle size also depends on the viscosity of the liquid being injected. Thus, needles need to be sufficiently long enough to inject the drug into the subcutaneous tissue and also taking into account the rate of administration. It is currently recommended that the required needle length is determined by using the lifted skinfold technique and selecting a needle that is 1.5 times the width of the skinfold. In general, the length of the needle is between 8 to 14 mm. However, the current needle length, size and the delivery rate often result in tissue damage at the site of injection. The present invention makes use of an improved needle, wherein the needle has a 5-18 thousands of an inch diameter vertices. Preferably, the length of the needle is from 2 to 10 mm. In a highly preferred embodiment, the volume of fluid administered occurs at a delivery rate of between about 0.5 ml / hour to about 8 ml / hour.

[0052] As discussed above, the use of known subcutaneous delivery methods is associated with tissue damage and / or pain at the site of administration. The present invention differs from the prior art since the injected fluid is given the ability to be absorbed at substantially the same rate, a similar rate, or a faster rate than the delivery rate at which the injection occurs. Currently, subcutaneous injections occur at rates up to 100 ml per hour, which results in dissected tissues with the fluid under pressure in a manner that causes, for example, tissue necrosis. By developing needles with a smaller vertices diameter and shorter in length, together with a reduced infusion rate the previous complications of subcutaneous delivery of a drug have been at least reduced or in some situations, eliminated.

[0053] A primary difference from the methods known in the art is that subcutaneous infusion of antibiotics with the known methods was usually over 5-30 minutes rather than by continuous infusion over 24 hours. By changing the infusion to 24 hours for subcutaneous infusions therate of delivery per hour is reduced. The dilution can be reduced further in special cases by having a higher total volume by having several, for example, 3-4 infusion sites but limiting each infusion site to less than 8 ml / hr based on our current research. Our research has defined that with very slow infusions concentration can be increased safely. This new concept for subcutaneous infusion will give similar blood levels as continuous intravenous infusions, with the possible exception of within the first hour or so.

[0054] We have found that the risk of tissue damage is reduced by limiting the rate of injection to less than 2.5 ml an hour. Rates of injection per site up to 8 ml / hr per hour will have a higher risk of causing tissue damage but it is expected to be safe for most, therapeutic agents, and in particular, antibiotics. For example, the concentration of 1 gram per ml will usually be toxic to tissues for many antibiotics but dilutions with 100 mg per ml will usually be accepted providing the infusion rate is less than 4 ml per hour. For intramuscular injections in contrast concentrations of 0.3 gram per ml are common. This concentration is also possible with subcutaneous infusions at very slow rates of 1 ml per hour.

[0055] In one embodiment, the invention involves continuous infusion of antibiotics at just over 1 ml per hour in solutions of 1 gram per 10 ml in the case of cefazolin to produce a fluid with a viscosity of a known level (e.g. 1.3) with the viscosity built into the infusion kit for the known antibiotic so that delivery will be accurate. This means infusion balloon pumps or spring driven syringes (e.g Springfusor™ pumps) will be labeled for the infusion of a particular antibiotic and its relevant correction factor for its dilution.

[0056] Our discovery from our research work confirms that the rate of injection plus concentration of the therapeutic agent determines the risk of tissue damage. Dilutions that have concentrations of 2 gram per 10 ml and infusion rates limited to less than 2 ml per hour potentially allow up to 50 ml per 24 hours (10 grams). With 30 ml and 60 ml Springfusor™ pumps the rate of fluid delivery with this concentration limit will allow 3 and 6 grams to be limited in 24 hours. Our initial experiments with some antibiotics will not allow this concentration. For most antibiotics the 8 ml per hour limit will limit necrosis and damage to tissue as absorption is effectively at the same rate as injecting into the tissues.

[0057] The method of the present invention avoids the problems of the prior art having the trend of delivering the majority of the antibiotic to the tissues in 30 minutes or less. Our method may allow a maximum of 200 mg per ml for cefazolin and a maximum infusion site delivery usually in the 2-4 ml per hour range (0.4-0.8 grams per hour). With these limits the maximum infusion rate will be limited to 0.8 gram per hour.

[0058] Thus, our method also allows two separate antibiotics to be delivered to two separate sites simultaneously.Furthermore, our method would allow patients themselves to fill their own syringes as the need for sterile management of the tubing is much reduced as the infection risks with central lines is much reduced.

[0059] We expect that our experiments will demonstrate that tissue damage might still be reduced with infusions above 4 ml per hour but the principal of teaching to avoid the previous practice of delivering all subcutaneous antibiotic treatments inside 30 minutes should be replaced to reducing risk by much slower delivery rates than that of known methods.

[0060] Antibiotic deliver in humans has been restricted to oral, intravenous (intermittent injections 8 or 12 hourly or continuous infusions), subcutaneously (intermittent injections usually with 20-100 ml) and with intramuscular injections.

[0061] The present invention makes use of a continuous subcutaneous infusions to avoid the troughs in blood levels with intermittent injections and also avoid the deaths associated with long term central line infections. The alternative of subcutaneous infusions to replace central line infusion have not been realised or taught.

[0062] The barriers to subcutaneous continuous infusions in the past appear to have been due to under appreciating the potential benefits, not knowing what concentration of subcutaneous antibiotics should be used, having no regulatory support or peer group support for continuous subcutaneous infusions, not knowing the viscosity correction factors for spring driven or elastomer driven (e.g. balloon) pumps and having no kits, information packages, teaching programs or regulatory support.

[0063] Our inventive work in this area has allowed us to start treating patients with subcutaneous cefazolin infusions. We have also validated ceftriaxone infusions. These patients have been treated using spring driven infusion pumps with corrections for viscosity based on the concentrations used. Concentrations of 1 gram, 2 grams and 3 grams per 10 ml of cefazolin all appear practical. Tables and data sets are possible for each antibiotic and infusion pump. These data, kits, regulatory packages and teaching are all part of the work to invent and make acceptable the concept of continuous antibiotic delivery.

[0064] 1. The benefits of continuous antibiotic infusions over subcutaneous bolus doses includes:

[0065] • the cannula should be soft and can be used continuously for several weeks in a row while with bolus doses the cannula is inserted to a new site every 8-12 hours.

[0066] • the blood levels are significantly higher than the 8 or 12 hourly infusions with a trough in blood levels before the next injection, and this delivers better blood levels above the MIC ( mean inhibitory concentration) and better treatment of infections.

[0067] • Less work. By setting up a continuous infusion for days there is less work than having to organise new injection sites every 8 or 12 hours.As infusions are only 0.5-8 ml an hour with subcutaneous infusions and usually less than 2mls an hour compared to 40-200 ml an hour the pain is usually less with slow continuous infusions.

[0068] • As the rate of infusions is often below 2 ml an hour and absorption into the tissues may be as fast as the infusion rate higher concentrations are possible than when injecting volumes of 50-100 ml which are often used with subcutaneous bolus injections.

[0069] The benefits of continuous antibiotic infusions Intravenous over Bolus Dosing

[0070] • the continuous infusion allows blood levels to be maintained at consistent levels significantly above the troughs that occur with 3 intravenous doses a day. Together with our local hospital, we calculated blood levels of cefazolin for our patients receiving continuous subcutaneous infusions of 6 mg a day compared to patients receiving 2 mg intravenously every 8 hours. The blood levels achieved continuously with the subcutaneous infusions based on his work for the 6 mg a day was 8.5 ng / ml compare with a trough of 3.5 ng / ml just before each injection. This predicts an improved response for all antibiotics where protecting mean inhibitory concentrations are important. We have demonstrated over 3 years the clinical value of continuous subcutaneous infusions with cefazolin and ceftriaxone in 10 patients.

[0071] • In the case of continuous or intermittent intravenous dosing over long periods of time central lines and peripheral central catheters are usually used. In the US there are up to 280,000 serious infections associated with central lines. These lines take organisms down to the heart valves and are spread organisms to tissues in all parts of the body. This leads in the US to 30,000 deaths a year and 250,000 people that require treatment for infections in intensive care units. In the case of subcutaneous infusions the infection of a subcutaneous catheter would cause pus to develop in the subcutaneous tissues that would be expelled easily without the risk of extensive infections usually.

[0072] The benefits of continuous antibiotic infusions Intravenous over Continuous Intravenous Infusions

[0073] • the advantage of maintaining constant blood levels without troughs is equally achieved with continuous intravenous and subcutaneous infusions.

[0074] • In the case of continuous or intermittent intravenous dosing over long periods of time central lines and peripheral central catheters are usually used. In the US there are up to 280,000 serious infections associated with central lines. These lines take organisms down to the heart valves and are spread organisms to tissues in all parts of the body. This leads in the US to 30,000 deaths a year and 250,000 people that require treatment for infections in intensive care units. In the case of subcutaneous infusions the infectionof a subcutaneous catheter would cause pus to develop in the subcutaneous tissues that would be expelled easily without the risk of extensive infections usually. This makes continuous infusions much safer if done with subcutaneous infusions.

[0075] 4. The benefits of continuous antibiotic infusions Intravenous over Intramuscular Injections:

[0076] • intramuscular injections are much more concentrated than what is used with subcutaneous injections usually. As an example with cefazolin prepared for intramuscular injections 1 gram is dissolved in 2.5 ml while intravenous and subcutaneous injections are usually dissolved in 10 ml. Where infusions are at really slow rates such as low as 0.4 ml an hour close to 4 mg a day can be delivered subcutaneously when concentrations are similar to those used with intramuscular injections. Subcutaneous infusions have the advantage of causing less pain and also allows much larger doses to be delivered with constant blood levels being achieved. The present invention realises the advantages of subcutaneous infusion. The improved sustained blood levels to prevent troughs give an advantage over intermittent delivery, while the move away from central line catheters eliminates the risk of damage and deaths from central line infections.

[0077] The present invention aims to provide for the subcutaneous infusion of antibiotics and other viscous medications to achieve a blood serum level that is therapeutically effective in the treatment of infections. Preferably, a therapeutically effective level serum level of antibiotic is achieved by a subcutaneous infusion of about 6 grams per 24 hours.

[0078] In one preferred embodiment the subcutaneous infusion are typically set up for about 10 days or more and may be delivered continuously for up to three weeks.

[0079] Kits

[0080] In one embodiment, the subcutaneous infusion is delivered in the form of a kit. In one highly preferred embodiment of the present invention, the kit comprises a length of tubing, a spring driven pump (e.g. Springfusor™) or an elastomer driven pump associated with a syringe, an appropriate ampoule of antibiotics and instructions on how much fluid to add to the syringe. By adding the appropriate volume of fluid, to create the appropriate volume and viscosity the tubing and pump will give a steady flow of fluid over 24, 48, 72, 96 or more hours. When the fluid in the first syringe is delivered another syringe will be filled and connected to the same flow control tubing.

[0081] The present inventions aims to design and deliver antibiotic ampoules plus tubing sets so that the tubing set can be attached to the subcutaneous needle and at the other end be attached to a known recommended syringe filled with saline or other diluent and a known quantity of antibiotics supplied with the kit.In this way the kit will inform the patient and their carer about the number of grams a day that will be delivered subcutaneously continuously. These kits will control the viscosity, flow rate, blood level to be achieved while the tissue levels will be dependent on patient issues such as blood supply, pressure and many issues. These kits will maximise the ability to promote continuous subcutaneous antibiotic delivery. In the case of the tubing set, the syringe may empty over 12, 24, 48 or 72 hours or more. When a spring driven pump, such as a Springfusor™ is used, the kits will usually be supplied with enough ampoules to allow the continuous infusion to continue for a much longer period of time and so a new syringe will be made up, the old empty syringe will be removed from the spring driven device (Springfusor) and the new syringe full of antibiotic will be attached to the resistance tubing calibrated to deliver a set number of grams of specific antibiotics per day.

[0082] For some of the antibiotic kits of the present invention, they will have a calibrated balloon driven device, labeled, where the device is calibrated to deliver a set number of grams of a specific antibiotics per day by using our data on viscosity, safety regarding infusion rates, and regulatory data on subcutaneous delivery of that antibiotic.

[0083] In some cases the kits can be used in special tissues with very poor blood supplies to be infused directly into areas with the poor blood supply.

[0084] The use of this technology is expected to empower general practitioners and non-medical people to give antibiotics at much higher MIC levels consistently to tissues and achieve cures of infections in damaged tissues as an outpatient with enormous savings in costs. For people in isolated settings it may allow earlier treatment of cellulitis in damaged tissues.

[0085] Thus, in one embodiment, the present invention provides kits for the continuous subcutaneous deliver of antibiotics as well as other viscous fluids that would benefit from subcutaneous delivery.

[0086] One embodiment of the kit comprises a length of plastic tubing, together with an ampoule of powder (e.g. antibiotic), creating the possibility of continuous subcutaneous antibiotic delivery with Mean Inhibitory Concentrations (MIC) even in general practice, than are orders of magnitude more efficient than the troughs in antibiotic levels that now occur in general medical practice.

[0087] This is achieved by using algorithms for each antibiotic (or other drug) requiring data sets delivered to regulatory bodies so that a simple pack can be set up by a nurse or even a nonmedical worker in a rural or isolated setting. The first previously unrealised point is to realise that energy storing devices such as elastomer (e.g. balloon) or spring driven syringes or compressed air driven devices that operate against a known resistor using Poiseuille’s law, can be used to deliver viscous antibiotics into the subcutaneous space if it is known what concentration and what pH is acceptable to tissues and if you can correct for the viscosity at thisconcentration as Poiseuille’s law requires viscosity to be considered in the calculation. In the past subcutaneous antibiotic delivery has been restricted to delivery of 15-30 ml of fluid subcutaneously every 8 hours with the problem that the kidneys typically drain out the antibiotic levels in the tissues with the result that the trough levels 8 hours later means the MIC of antibiotics is not high enough to be actively killing the organism.

[0088] The kit of the present invention is designed to deliver a lowest cost, user friendly, new product, based on algorithms which are based on regulatory approved data sets which are already calculated into the product so that the patient themselves could add saline, use a subcutaneous soft plastic cannula and pick up some abdominal fat and insert the cannula and then receive continuous antibiotics with high MIC levels of antibiotics for days from stored energy delivered with the kit.

[0089] In our designs and experiments the lowest cost version contained three very large antibiotic ampoule, a piece of tubing and three syringes. In this model the syringe (e.g. 100 ml) was filled with the antibiotic powder and saline added to fill the syringe, the tubing with appropriate resistance (pre-calculated for use) was connected to the subcutaneous site and the syringe when connected to the tubing was connected to a Springfusor™ pump to drive the fluid at the appropriate infusion rate.

[0090] At the end of a set period, such as three days delivering, for example 3.3 grams of cefazolin per day was delivered subcutaneously and continuously, a second syringe could be filled and then added to the same tubing to replace the first syringe. This example contrasts with a set of three infusion balloon pumps, packaged with 3 ampoules. In this example a new balloon and a new set of tubing is required for each three day infusion. The commercial cost of a syringe compared to an infusion balloon is about 50-100 times greater for the infusion balloon making the Springfusor™ pump with tubing and an ampoule with all the data and regulatory work designed into the product creating the cheapest and easiest subcutaneous products.

[0091] Our group has investigated the use of Springfusor™ pumps to regularly deliver cefazolin or ceftriaxone subcutaneously for days or weeks in mobile patients so as to achieve high continuous levels of antibiotic with high MIC levels.

[0092] The above concept is essential for an industry that has popularised the use of long term central and peripherally inserted central catheters (PICC). Within days after the insertion of central catheters, organisms start travelling along the catheters. These organisms are often resistant to the antibiotics being infused, leading to a significant increase in patient death or transfer to intensive care which incurs increased costs.

[0093] Although pressure driven pumps have been used for intravenous infusions, the viscosity correction, safe dilution levels and regulatory data for subcutaneous infusions is not known or unavailable. Therefore, the combination of the kit of the present invention provides animprovement or at least a useful alternative to the delivery of antibiotics and other viscous medications.

[0094] For each antibiotic appropriate concentrations can be made up and validated. Viscosities for each standardised concentration will be matched with appropriate pumps so that those with access to the data sets can easily do continuous subcutaneous delivery. Regulatory work will involve providing hospitals, groups of doctors and regulatory groups access to these data sets so that subcutaneous infusions will be easy with these data sets.

[0095] Examples

[0096] Example 1: Validation of a delivery rate on reducing or eliminating tissue damage In the first instance we will confirm our initial studies that a delivery rate of 1.25 ml per hour avoids, reduces, or eliminates tissue damage associated with known subcutaneous injection techniques.

[0097] We will measure the amount of tissue necrosis at the site of subcutaneous delivery using standard techniques in order to assess any tissue damage. For example, we will measure inflammation (e.g. neutrophil infiltration), focal parakeratosis, necrosis of the dermis, necrosis of the muscularis, and haemorrhage to access the level of tissue damage.

[0098] We will then validate a delivery rate of 2.5 ml per hour and 4 ml per hour to confirm that these rates also avoid, reduce, or eliminate tissue damage associated with subcutaneous injections.

[0099] Example 2: Reduction of the concentration of a therapeutically active agent

[0100] We will investigate the impact on limiting the concentration of an antibiotic (as an example of an active agent), in a pharmaceutical composition, given most antibiotics are well tolerated in the tissue for a critical concentration. For example, the tissues might be able to cope with only 10 mg / ml of the antibiotic. This would allow 100mg / 10 ml and 1 gram per 100 ml of the antibiotic to be delivered over a continuous period of time. It may also be possible to dilute the antibiotic to a certain level, such as 0.5 g delivered in 100 ml to achieve a therapeutic effect and avoid, reduce or eliminate tissue damage associated with known subcutaneous injection techniques. In order to deliver a maximum of just over 1 ml per hour we will use a Springfusor™ pump (100 ml) to control the delivery of the 100 ml volume at one to four separate sites. The one to four separate sites will be located at the umbilical region of the abdomen. The use of the pump ensures that the pharmaceutical composition is delivered at a constant rate.

[0101] When four needles are used, the four separate needles will be connected to four separate tubing lines will be connected to the pump. The flow rate for each of the tubing and need will be set at 1 ml / hour.After delivery has been completed, we will measure the amount of tissue damage using standard techniques. In particular, we will measure the amount of tissue necrosis.

[0102] Each antibiotic will have a limited tolerated concentration and a limited rate per hour that can be delivered per hour at each site. By working out the maximum tolerated concentration and the maximum volume per hour it is possible to deliver most antibiotics subcutaneously without causing tissue necrosis.

[0103] We anticipate that the results of this study will deliver from 1-4 ml per hour per site allows subcutaneous antibiotic delivery to be safely for most antibiotics. Continuous infusions to subcutaneous tissues 24 hours a day gives very similar blood levels to intravenous delivery for most antibiotics.

[0104] This subcutaneous antibiotic delivery technology involves limiting volumes typically to 1 -4 ml per hour, defining the maximum concentration allowed or maximum number of milligrams per hour that the tissues can tolerate. The prior art typically injects a subcutaneous dose into the tissues once a day over 5-30 minutes and this results in scarring and necrosis of tissues. This new information of limiting the volume and concentration per hour has allowed subcutaneous antibiotics to become safe and provide the same tissue concentration as can be achieved with continuous intravenous infusion without the risks of infections that arise from central line infusions.

[0105] Example 3: Kits for the Delivery of Antibiotics and other Viscous Medications

[0106] We describe new packaging systems and kits where pressure driven pumps in the form of elastomer (e.g. balloons) or spring driven pump syringes (e.g. Springfusor™) and resistance tubing can be packaged with an appropriate ampoule. Together they form a kit where the manufacturer has calculated the viscosity correction factor and the desirable infusion rate and facilitated the user being able to trickle drugs in subcutaneously instead of using central lines at typical infusion rates at just 1-2 ml per hour at dilutions which will not irritate tissues that the manufacturer has confirmed by his research.

[0107] This invention then creates a new industry where potentially viscous and non-viscous drugs are sold with ampoules plus packages with potential energy from elastomeric or spring driven pumps are sold as a package to popularise subcutaneous continuous infusion delivery at appropriate rates for any antibiotic or other drug that can be delivered subcutaneously.

[0108] The kits are designed to deliver a continuous infusion of antibiotics (or other viscous medications) at about 1 ml per hour in solutions of 1 gram per ml in the case of cefazolin, to produce a fluid with a viscosity of known level (e.g. 1.3 for cefazolin) with the viscosity built into the infusion set for the known antibiotic so that delivery will be accurate.Elastomer (Balloon) Pump Kit.

[0109] The kit comprises the following components:

[0110] A needle for subcutaneous injection. Preferably the needle has a 5-18 thousands of an inch diameter vertices, a length of 2mm to 10 mm;

[0111] A 100 ml balloon pump;

[0112] Flow control tubing. Preferably, the flow control tubing is designed to deliver 90 ml of fluid with a viscosity of 1.3 over a 72 hour period;

[0113] Saline Solution (sterile). Three ampoules of 30 ml of saline solution or a 100 mg saline bag; An antibiotic - Cefazolin (powder). In this example, three ampoules of cefazolin may be delivered in a saline solution. The cefazolin powder is dissolved in 100 ml of saline solution. This will deliver 3 grams of cefazolin subcutaneously per 24 hours for three days.

[0114] In this example, cefazolin (Apotex) 10 grams with a 100 ml balloon calibrated to deliver 39 ml of saline per 24 hours subcutaneously, (equivalent to 3 grams of cefazolin) at a dilution of 1 gram per 10 ml at a viscosity of 1.3 adjusted to be delivered every 24 hours for 3 days.

[0115] In another example, cephazolin (Apotex) 10 grams with a 100 ml balloon calibrated to deliver 68 MLS of saline per hour or 50 ml of cefazolin at a viscosity of 1.3 per 24 hours. This product will deliver 5 grams of cefazolin subcutaneously or intravenously per 24 hours. The continuous delivery will maintain the mean inhibitory level constant despite renal function bringing the blood levels of down continuously. As a subcutaneous product delivered as 5 grams per 24 hours for two days should meet the needs in most infections without the risk of centreline infections with resistant organisms.

[0116] In a further example, cephazolin (Apotex) 10 grams with a 100 ml balloon calibrated to deliver 130 MLS of saline in 24 hours will deliver 100 ml of cefazolin of cefazolin dissolved at 1 gram per 10 MLS so that 10 grams will be delivered subcutaneously or intravenously over 24 hours.

[0117] Springfusor™ Pump Kit

[0118] The kit comprises the following components:

[0119] A needle for subcutaneous injection. Preferably the needle has a 5-18 thousands of an inch diameter vertices, a length of 2mm to 10 mm;

[0120] A Springfusor™ pump (or springe driven pump). The Springfusor™ is a spring-driven, lightweight multiple use pump. W hen used with Flow Control Tubing (FCT) is intended to provide constant intravenous (IV) or subcutaneous (SC) infusions in either a 10ml, 30ml or 50ml configuration at a variety of pre-set flow rates. It requires no programming or external powersource and is simple to use, with only minimal training required (see for example, US Patent 11,090,428);

[0121] Flow control tubing. Preferably, the flow control tubing is designed to deliver 90 ml of fluid with a viscosity of 1.3 over a 72 hour period;

[0122] Saline Solution (sterile). Three ampoules of 30 ml of saline solution or a 100 mg saline bag; An antibiotic - Cefazolin (powder). In this example, three ampoules of cefazolin may be delivered in a saline solution. The cefazolin powder is dissolved in 100 ml of saline solution. This will deliver 3 grams of cefazolin subcutaneously per 24 hours for three days.

[0123] In the same way as described above for the elastomer pump, the 30 ml Springfusor™ pump can be calibrated to deliver 3 grams of cefazolin with a 1.3 correction for viscosity from a 30 Springfusor per 24 hours, and 60 ml Springfusor can be calibrated to deliver 3 grams per 24 hours for 2 days and 100 ml Springfusor can be calibrated to deliver 3 grams per day for 3 days.

[0124] 60 ml Springfusor can be calibrated to deliver 5 mg per day from 5 grams of cefazolin (Apotex) so that the 60 ml Springfusor can deliver 5 mg per day.

[0125] In another example, a 100 ml Springfusor can be calibrated with its 1.3 viscosity correction made in its resistor tubing to deliver 5 grams per 24 hours for 2 days. The 100 ml Springfusor with its 10 gram cefazolin ampoule can be adjusted to deliver its 10 gram over 24 hours intravenously.

[0126] Flow Control Tubing Kits

[0127] In some instances, balloon pumps will not be used. An example is wherein a 60 ml set of tubing with a 60 ml syringe and two sets of the 3 gram ampoules of Cefazolin (Apotex) is prepared. The tubing kit will be adjusted to deliver 30 ml a day of 3 grams of cefazolin at room temperature and the other parts of the kit (such as saline solution, needle) will be added.

[0128] The new kits will facilitate safter antibiotic administration and the kits will make it easy for any General Practitioner to deliver to a patient up to 60 9 grams a day of antibiotics that does not have to be hospitalised.

[0129] Example 4 Subcutaneous Infusions - Cefazolin

[0130] The following provides several examples of the present invention using cefazolin as the antibiotic to deliver a therapeutically effective amount of the antibiotic.

[0131] In order to achieve the desired infusion rate of between about 5 to about 10 grams per 24 hours, the appropriate tubing is required. For example, for cefazolin subcutaneous infusion, the following tubing may be used in combination with the appropriate Springfusor™ and syringe volume (e.g. 30 ml, 60 ml or 100 ml syringe).To achieve a subcutaneous infusion of cefazolin at 6g per 24 hours, tubing having an internal diameter of 2.65 thou (0.06731 mm) and a length of 57 mm is used with a 30 ml syringe and the Springfusor. This results in the delivery of 12 g of cefazolin is administered after 2 days.

[0132] To achieve a subcutaneous infusion of cefazolin at 3g per 24 hours, tubing having an internal diameter of 2.65 thou (0.06731 mm) and a length of 110 mm is used with a 30 ml syringe and the Springfusor. This results in the delivery of 12 g of cefazolin after 4 days.

[0133] (a) Subcutaneous infusions cefazolin

[0134] Large volume infusion baxter

[0135] LVI 2C 1009 KP infusor LV5

[0136] Add 20 gram to 185 ml saline which delivers 3.84 ml per hour and 10 grams per 24 hours. Add 10 gram to 218 ml at 4.5 ml per hour and 5 grams per 24 hours.

[0137] 4 Grams Cephazolin. per 24 hours.

[0138] Nipro Surefuser Disp. Elastomeric Infusion Pump 100ml Green 2.1ml / hr.

[0139] Add 8 grams of cefazolin to 80 ml saline to deliver 39 ml per 24 hours to deliver 4 grams per 24 hours for 2 days.

[0140] Apotex 10 gram container.

[0141] 100 MLS saline delivers Springfusor™.

[0142] (b) To investigate 50 ml per hour.

[0143] Equals 65 ml per 24 hours hour (+10 grams cefazolin) gives 5 grams per 24 hours.

[0144] 130 ml per hour (add 10 grams of cefazolin in 100 ml saline) delivers 100 ml in 24 hours.

[0145] 100 sterile samples of each of the following were prepared.

[0146] 30 ml Springfusor™ giving 3 grams / 24 hours.

[0147] 1 ) 39 ml per 24 hour tubing flow rate (average 1.625 ml per hour). This will deliver 30 ml of fluid with a viscosity of 1.3.

[0148] Label - designed to deliver 30 MLS / 24 hours of cephalosporins at 1 gram per 10 ml of saline with a viscosity of 1.3.

[0149] Calibrate 30 ml Braun luer lock if practical. Alternatively is the use of JMS.

[0150] 60 ml Springfusor™ at 6 grams per 24 hours.

[0151] 2) 78 ml an hour from a 60 ml Springfusor. 3.25 ml an hour average.

[0152] Label - designed to deliver 60 ml per 24 hours of cephalosporins at 1 Gram per 10 ml with a viscosity of 1.3 ( delivers 6 grams per 24 hours)60 ml Springfusor™ giving 3 grams a day of cefazolin for 2 days

[0153] 3) 39 ml per 24 hours from a 60 ml syringe.

[0154] Label - designed to deliver 3 grams per 24 hours of cephalosporins at 1 gram per 10 ml with a viscosity of 1.3. (delivers 3 grams per 24 hours for 2 days).

[0155] 100 Springfusor™ to deliver 10 grams per 24 hours.

[0156] 4) 130 MLS per 24 hours for a 100 ml Springfusor. This is designed to deliver 10 grams of cephalosporins in 100 ml delivered over 24 hours.

[0157] Label - designed to deliver 10 grams of cephalosporins in 100 ml over 24 hours.

[0158] 100 ml Springfusor™ for 5 grams per 24 hours for 2 days.

[0159] 5) 65 ml per 24 hours from a 100 ml Springfusor. This is designed to deliver 5 grams per 24 hours of cephalosporins with 10 grams dissolved I. 100 ml of saline over 2 days.

[0160] 100ml Springfusor™ 3.3 grams of cefazolin per 24 hours for 3 days.

[0161] 6) Flow rate 43.3 MLS per 24 hours. This delivers 33 ml per 24 hours. Add 10 grams to a 100 ml syringe. Add the tubing designed for 43.3 ml per 24 hours.

[0162] Example 5 - Cefazolin Subcutaneous Delivery

[0163] In the case of cefazolin at a concentration of 2 grams per 10 ml, the viscosity is close to 2 (1.9) at room temperature (20 degrees centigrade). One can therefore predict that a balloon infusion pump set to deliver 2 ml an hour will deliver just over 1 ml per hour at this concentration with a result of delivering 1 gram every 4-5 hours. As a result, one can prepare instructions (e.g. a label) for a commercial ballon pump set to run at 2 ml an hour which can be added to the pump at a time of adding cefazolin in a concentration of 20 grams per 100 ml to the pump.

[0164] This label can be added to the pump as a product that explains that the pump contains 20 grams of cefazolin expected to deliver at close to 5 grams a day over a 4 day period. Our product would include a label to be added to the pump or on the pump that explained how to give 5 grams of cefazolin a day when connected to a subcutaneous needle.

[0165] A further embodiment by way of example, may be an infusion balloon plus a label with the data set described above, a subcutaneous needle such as the BD saf-T-lntima Set and ampoules of a specific antibiotic such as 2 ampoules of 10 gram of cefazolin manufactured with labels for subcutaneous infusions.

[0166] The kit might be for use by rural doctors, those on ships, general practitioners, diabetic clinics or anyone dealing with cellulitis. If the ballon pump was initially labeled for 2 ml per hour then adding 20 grams per 100 ml of saline would deliver 5 grams per day. If the balloon driven or spring driven pump was labeled initially for 4 ml per hour the infusion would deliver 10 grams a day and would be expected to achieve more than 12 mg / L (12 ng / ml) in the plasma andtissues of the patient treated. Making up kits with this level of information could make it possible to achieve the same results in rural settings with cellulitis as we can in intensive care units now. A further embodiment is a simple kit comprising ampoules of an antibiotic such as cefazolin with a label stating approved for subcutaneous continuous infusion at a fixed concentration and rate, together with a label describing the infusion rate and expected serum concentration expected from that infusion and a length of tubing that acts as a flow control tubing for a Springfusor™ designed for 30, 60 or 100 ml infusion pumps that would deliver cefazolin or other antibiotic at an appropriate infusion rate.

Claims

CLAIMS1. A method to avoid, reduce or eliminate tissue damage associated with subcutaneous injection of a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutic agent in an injection fluid, the method comprising the use of one or more needles, wherein the size of the needle is about 2 to about 10 mm in length, wherein the infusion rate of the pharmaceutical composition is about 1 ml / hour to 8 ml / hour, and wherein the infusion rate of the fluid is substantially the same as, similar to or less than the rate that the fluid is absorbed by the tissue at or around the injection site.

2. A method to avoid, reduce or eliminate tissue damage associated with subcutaneous injection of a pharmaceutical composition, wherein the pharmaceutical composition comprises a therapeutic agent in an injection fluid, the method comprising diluting the amount of the therapeutic agent to a concentration that is between 0.5 g / 100 ml to 4.0 g / 10 ml administered over a continuous infusion rate of about 1 ml / hour to about 4 ml / hour.

3. The method of claim 1, wherein the method comprises diluting the amount of the therapeutic agent to a concentration that is between 0.5 g / 100 ml to 4.0 g / 10ml administered over a continuous infusion rate of about 1 ml / hour to about 8 ml / hour.

4. The method of any one of claims 1-3, wherein the method further comprises the use of a pump to continuously deliver the pharmaceutical composition at a constant rate.

5. A kit for the subcutaneous continuous delivery of a therapeutic agent, comprising:(i) an energy storage pump device;(ii) a length of calibrated tubing;(ii) at least one ampoule comprising the therapeutic agent;(iii) a saline solution in an ampoule(s) or bag(s);and optionally one or more needles suitable for subcutaneous injection,and instructions for use.

6. The kit according to claim 5, wherein the energy storage pump device is selected from a spring driven pump or an elastomer pump.

7. The kit according to claim 5 or claim 6, wherein the therapeutic agent is selected from the group comprising: cephalosporins, ceftriaxone, cefazolin, ertapenem, teicoplanin, amoxicillin and other penicillins and also aminoglycosides.